Why I’d avoid this 4.5% dividend yielder and buy GlaxoSmithKline plc instead

This 4.5% dividend yielder may look attractive, but here’s why my money would go on GlaxoSmithKline plc (LON: GSK)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Engineering services company Babcock International Group (LSE: BAB) released a trading update this morning and the shares are down around 2.5% as I write, at 636p. Considering the wider market carnage, that fall isn’t too bad, but I think there are some areas for mild concern in the statement.

In line with expectations

The directors expect full-year earnings and cash conversion to be in line with their expectations, which tells us that nothing has thrown the outlook. City analysts following the firm forecast growth in earnings per share of 3% for the trading year to March 2018 and 4% the year after that. That’s nothing to become excited about, but it’s better than a decline in expected earnings.

Although earnings aren’t growing fast, the quality of those earnings looks like it is improving. The directors say that margins will be higher than they thought for the year “due to a combination of more favourable margin mix and a continued management focus on efficiency improvements.” But although margins are rising, revenue is falling and looks set to come in “slightly lower” than expected at between £5.3bn and £5.4bn.

Revenue under pressure

Revenue is under pressure because of ongoing “tough trading conditions and short cycle order placement delay” in the offshore and oil & gas sector. There has also been a slowdown in volumes relating to defence sector commodity and spares procurement, and “slower mobilisation on the MSSP equipment and engineering management contract for MoD.”

Should we be worried? Maybe. The dividend yield for the current year sits at around 4.6% with the payment set to be covered a healthy-looking 2.8 times by forward earnings. Over four years, the dividend has grown 26%, but that’s the main attraction from an investment point of view, because earnings growth is so pedestrian.

Strong bidding activity continued during the second half of the year and the short-term bid pipeline has increased to around £12.5bn, driving a “combined order book and near-term opportunity pipeline at £31bn.” However, I reckon there’s a fair degree of cyclicality in the operational set-up, which could send earnings and the dividend into reverse at some point if the economic sun stops shining, so I’d rather take my chances with defensive pharmaceutical firm GlaxoSmithKline (LSE: GSK).

An attractive dividend

When it comes to medicines, demand is far less cyclical, which means we can invest in GlaxoSmithKline with reasonable confidence that the cash flowing into the business will remain constant whatever the economic weather. To me, that situation makes the dividend yield of around 6.4% attractive. However, I’m not expecting rapid growth in either the dividend or in earnings. The dividend payment has been flat for around five years and the firm is struggling to grow earnings. The well-reported problems big pharmaceutical firms have endured due to patent expiry has allowed generic competition to swoop in, pulling the rug from margins on many of GlaxoSmithKline’s big-selling drugs.

Back in October, the firm’s third-quarter results suggested ongoing workmanlike progress rebuilding earnings. We can find out more about the headway being made with the full-year results due tomorrow, Wednesday 7 February. I’m expecting more of the steady operational advances we’ve seen lately.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentoned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 14% in 2024, what’s next for the Lloyds share price?

This Fool takes a closer look at what prompted the Lloyds share price to rise this year, and offers her…

Read more »

Investing Articles

5 FTSE 100 stocks to consider for a lifetime of passive income

I see lots of cheap dividend stocks in the FTSE 100 right now, but prices are starting to rise. Here's…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

3 growth stocks I’m desperate to buy as the FTSE 100 dips

Never waste a dip, says Harvey Jones. Three of his favourite growth stocks have fallen over the last month and…

Read more »

Investing Articles

I’d use a £10K ISA to try and generate £900 in dividends annually like this!

Christopher Ruane explains how he would invest a Stocks and Shares ISA in blue-chip companies to try and set up…

Read more »

Investing Articles

Here’s how I’d build a second income stream worth £1,228 a month by investing £10 a day!

A second income stream could come in handy later in life. This Fool explains how she’d build one by investing…

Read more »

Investing Articles

5 FTSE 250 stocks I’d buy for a lifetime of passive income

Here's why I think the FTSE 250 could be the best UK stock market index to go for in 2024…

Read more »

Union Jack flag triangular bunting hanging in a street
Investing Articles

Buy cheap FTSE shares, says HSBC

Analysts at HSBC have upgraded their rating of FTSE stocks and reckon the blue-chip UK index could carry on powering…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

It could be worth buying the dip for this FTSE 250 stock, down 7% today

Jon Smith spots a sharp drop in a FTSE 250 stock but explains why this could just be a blip…

Read more »